<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46950">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01966627</url>
  </required_header>
  <id_info>
    <org_study_id>1104008388</org_study_id>
    <secondary_id>R01HD040787</secondary_id>
    <nct_id>NCT01966627</nct_id>
  </id_info>
  <brief_title>Genetics of Fatty Liver Disease in Children</brief_title>
  <official_title>Genetics of Fatty Liver Disease in Childhood Obesity.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to investigate genetic predisposition to hepatic steatosis and the
      expression of gluconeogenic and lipogenic genes in livers of obese children and adolescents.

      Hypothesis 1: Common variants recently associated with variation in plasma TG levels
      identified in Genome Wide Association Studies (GWAS) (such as GCKR, PNPLA3) can affect
      accumulation of fat and subsequent development of Non Alcoholic Fatty Liver Disease (NAFLD).
      Gene variants act in additive or synergistic manner with progressive liver fat accumulation
      per additional risk allele.

      Hypothesis 2: With increase in hepatic fat content NASH and fibrosis will increase.
      Furthermore, expression of lipogenic markers (SREBP1c) will increase.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To establish a cohort of obese youths to prospectively analyze potential factors (genetic
      and nutritional factors) that might affect the expression and progression of NAFLD. This
      study will determine genetic markers and their ability to convey susceptibility to NAFLD in
      obese children and adolescents. Furthermore, potential mechanisms that might contribute to
      the accumulation of hepatic Triglyceride (TG) accumulation will be, for the first time,
      assessed by genotyping. Additionally, we will examine the presence of intestinal microbiome
      in the development of fatty liver through stool collection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>gene expression</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>gene mutation allele variation identification measure via gene extraction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hepatic fat content</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Abdominal MRI to measure liver fat and subcutaneous and visceral fat ratio done at baseline and 2 year follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glucose tolerance</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>glucose tolerance status measured by 3 hour oral glucose tolerance test done at baseline and 2 year follow up</description>
  </secondary_outcome>
  <other_outcome>
    <measure>DNA gene sequencing of intestinal bacteria's</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measure microbiota diversity via stool samples to understand variance of triglycerides accumulation in liver</description>
  </other_outcome>
  <other_outcome>
    <measure>Use liver biopsy specimen to assess differences in gene expression, as well as inflammation.</measure>
    <time_frame>As indicated by Pediatric Hepatolgist</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Non Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Pediatric NAFLD Cohort</arm_group_label>
    <description>Overweight and obese children and adolescents at risk for non alcoholic fatty liver disease will undergo oral glucose tolerance testing (ogtt), genotyping, abdominal and liver magnetic resonance imaging (mri), and will provide a stool sample at baseline and at 2 year follow up. A small subset will undergo liver biopsy to test for hepatic steatosis and nonalcoholic steatohepatitis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ogtt</intervention_name>
    <description>oral glucose tolerance test</description>
    <arm_group_label>Pediatric NAFLD Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>genotyping</intervention_name>
    <description>genotyping to look for risk alleles</description>
    <arm_group_label>Pediatric NAFLD Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>abdominal and liver magnetic resonance imaging</intervention_name>
    <description>magnetic resonance imaging scan of abdomen and liver - abdominal and liver mri</description>
    <arm_group_label>Pediatric NAFLD Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>stool sample</intervention_name>
    <description>stool sample taken to investigate metabolites</description>
    <arm_group_label>Pediatric NAFLD Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>liver biopsy</intervention_name>
    <description>liver biopsy to examine for cellular change and steatosis</description>
    <arm_group_label>Pediatric NAFLD Cohort</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The majority of the research subjects will be recruited from the Yale Pediatric Obesity
        Clinic and the Endocrine Clinic.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  between 7 and 18 years of age,

          -  overweight or obese with a BMI greater than the 85th percentile for age and gender,
             and

          -  be otherwise healthy.

        Exclusion Criteria:

          -  the use of any medication that alters liver function, blood pressure, glucose or
             lipid metabolism and

          -  no use of any antipsychotic medication

          -  Youth on chronic anti-inflammatory medications or who consume alcohol are also
             excluded.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sonia Caprio, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melissa Shaw, B.A.</last_name>
    <phone>203-785-6459</phone>
    <email>melissa.m.shaw@yale.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bridget Pierpont, M.A.</last_name>
      <phone>203-785-2942</phone>
    </contact>
    <investigator>
      <last_name>Sonia Caprio, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Burgert TS, Taksali SE, Dziura J, Goodman TR, Yeckel CW, Papademetris X, Constable RT, Weiss R, Tamborlane WV, Savoye M, Seyal AA, Caprio S. Alanine aminotransferase levels and fatty liver in childhood obesity: associations with insulin resistance, adiponectin, and visceral fat. J Clin Endocrinol Metab. 2006 Nov;91(11):4287-94. Epub 2006 Aug 15.</citation>
    <PMID>16912127</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 16, 2013</lastchanged_date>
  <firstreceived_date>July 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Sonia Caprio</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>non alcoholic fatty liver</keyword>
  <keyword>childhood obesity</keyword>
  <keyword>genetic variants</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
